Mak Quentin, Greig Julian, Ahmed Kamran, Khan Shamim, Dasgupta Prokar, Malde Sachin, Raison Nicholas
GKT School of Medical Education, King's College London, London, UK.
MRC Centre for Transplantation, Guy's Hospital, King's College London, London, UK.
Int Neurourol J. 2023 Jun;27(2):79-87. doi: 10.5213/inj.2346052.026. Epub 2023 Jun 30.
Urinary tract infection (UTI) is a common condition defined as the presence of bacteria within the urine above a certain threshold (usually >100,000 m/L). The lifetime risk in women is estimated to be 50%, of whom 25% will develop recurrence within 6 months. Unfortunately, the use of antibiotics to treat and manage recurrent UTI (rUTI) is a growing problem, due to the burden of growing antibiotic resistance on public health. As such, new approaches to manage rUTI are being investigated and developed. Competitive inoculation via instillation of Escherichia coli 83972 or HU2117 in the bladder is a new prophylactic non-antimicrobial therapy for rUTIs. It utilizes the principle of the protective nature of asymptomatic bacteriuria to prevent recurrence of symptomatic UTIs. However, the effectiveness and safety of this technique remains unclear. This systematic review examined the current outcomes data on competitive inoculation as an effective and safe treatment for rUTI prophylaxis. Based on a limited number of studies, current evidence suggests that competitive inoculation is an effective and safe prophylactic measure against UTIs in a select group of patients with incomplete bladder emptying. However, administration of the technology is both resource and time intensive, and there is strong data demonstrating low successful colonisation rates. Competitive inoculation is an alternative to antibiotics only to rUTI patients with incomplete bladder emptying. There is no evidence to suggest that the technology would be suitable for other subsets of rUTI patients. Further randomized controlled trials should be conducted to improve the evidence base before drawing conclusions for clinical practice, and ideas to improve colonisation rates and simplify the administration process should be explored.
尿路感染(UTI)是一种常见病症,定义为尿液中细菌数量超过一定阈值(通常>100,000个/mL)。据估计,女性一生中患尿路感染的风险为50%,其中25%会在6个月内复发。不幸的是,由于抗生素耐药性对公共卫生造成的负担日益加重,使用抗生素治疗和管理复发性尿路感染(rUTI)正成为一个日益严重的问题。因此,正在研究和开发管理rUTI的新方法。通过向膀胱内注入大肠杆菌83972或HU2117进行竞争性接种是一种针对rUTI的新型预防性非抗菌疗法。它利用无症状菌尿的保护性质原理来预防有症状UTI的复发。然而,该技术的有效性和安全性仍不明确。本系统评价研究了关于竞争性接种作为预防rUTI的有效和安全治疗方法的当前结果数据。基于有限数量的研究,目前的证据表明,竞争性接种对于一组膀胱排空不全的特定患者是预防UTI的有效且安全的预防措施。然而,该技术的实施既耗费资源又耗时,并且有强有力的数据表明定植成功率较低。竞争性接种仅适用于膀胱排空不全的rUTI患者,作为抗生素的替代方法。没有证据表明该技术适用于rUTI患者的其他亚组。在得出临床实践结论之前,应进行进一步的随机对照试验以完善证据基础,并且应探索提高定植率和简化给药过程的方法。